Hyloris Pharmaceuticals Future Growth
Future criteria checks 6/6
Hyloris Pharmaceuticals is forecast to grow earnings and revenue by 77.4% and 59% per annum respectively. EPS is expected to grow by 55.7% per annum. Return on equity is forecast to be 51.2% in 3 years.
Key information
77.4%
Earnings growth rate
55.7%
EPS growth rate
| Pharmaceuticals earnings growth | 21.4% |
| Revenue growth rate | 59.0% |
| Future return on equity | 51.2% |
| Analyst coverage | Low |
| Last updated | n/a |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2024 | 41 | 8 | N/A | 0 | 1 |
| 12/31/2023 | 15 | -8 | N/A | -10 | 2 |
| 12/31/2022 | 10 | -11 | N/A | -10 | 2 |
| 12/31/2021 | 3 | -12 | -12 | -11 | N/A |
| 9/30/2021 | 2 | -12 | -13 | -13 | N/A |
| 6/30/2021 | 1 | -12 | -14 | -14 | N/A |
| 3/31/2021 | 1 | -10 | -7 | -7 | N/A |
| 12/31/2020 | 0 | -7 | -5 | -5 | N/A |
| 9/30/2020 | 0 | -8 | -5 | -4 | N/A |
| 6/30/2020 | 0 | -8 | -5 | -4 | N/A |
| 3/31/2020 | 0 | -6 | -8 | -6 | N/A |
| 12/31/2019 | 0 | -5 | -6 | -5 | N/A |
| 12/31/2018 | 0 | -6 | -5 | -5 | N/A |
| 12/31/2017 | 0 | -4 | -4 | -2 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 52U is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.01%).
Earnings vs Market: 52U is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 52U is expected to become profitable in the next 3 years.
Revenue vs Market: 52U's revenue (59% per year) is forecast to grow faster than the German market (4.6% per year).
High Growth Revenue: 52U's revenue (59% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 52U's Return on Equity is forecast to be very high in 3 years time (51.2%).